Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Emergent BioSolutions Inc EBS

Healthcare Biotechnology
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial... see more

Recent & Breaking News (NYSE:EBS)

Data from Historic Phase IIb Clinical Trial for Tuberculosis Vaccine Candidate MVA85A Published in The Lancet

Business Wire February 4, 2013

Emergent BioSolutions to Release Fourth Quarter and Full Year 2012 Financial Results and Conduct a Conference Call on March 7, 2013

Business Wire February 1, 2013

Emergent BioSolutions Initiates Phase 2 Study in Pursuit of a Post-Exposure Prophylaxis Indication for BioThrax

Business Wire January 22, 2013

Emergent BioSolutions Initiates Phase 2 Clinical Trial for Next Generation Anthrax Vaccine NuThrax

Business Wire January 17, 2013

Emergent BioSolutions Announces Preliminary 2012 Financial Results and Provides Guidance for 2013

Business Wire January 7, 2013

Improving Trend in FDA First Cycle Review Approvals a Major Factor for Biotech Industry's Success in 2012

Marketwired January 3, 2013

Free Research Reports on CAR, EBS, SIRI and X Issued by the Bedford Report

Marketwired January 3, 2013

Emergent's TRU-016 for CLL Receives Orphan Medicinal Product Designation from European Commission

Business Wire January 2, 2013

Emergent BioSolutions Secures Exclusive U.S. Commercial Rights to Next Generation Pandemic Influenza Vaccine Candidate

Business Wire December 28, 2012

Time for a Santa rally?

Matt Stiles December 11, 2008

Looking for Relative Strength

Matt Stiles November 13, 2008

Beware the value trap

Matt Stiles October 23, 2008